Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Internal Medicine C, Greifswald University Medical Center, Greifswald 17475, Germany.
Trends Biochem Sci. 2021 Jul;46(7):522-524. doi: 10.1016/j.tibs.2021.04.001. Epub 2021 Apr 17.
Valencia-Sánchez et al. have demonstrated that two histone post-translational modifications (PTMs) - H4K16 acetylation (H4K16ac) and H2BK120 ubiquitination (H2Bub) - enhance the methylation of H3K79 (H3K79me) by Dot1. This breakthrough indicates crosstalk between H4Kac/H2Bub/H3K79me and may improve our understanding of the role that Dot1/Dot1L plays in developmental processes and disease, including MLL1/KMT2A(MLL-r) leukemia.
瓦伦西亚-桑切斯等人证明了两种组蛋白翻译后修饰（PTMs）-H4K16 乙酰化（H4K16ac）和 H2BK120 泛素化（H2Bub）-增强 Dot1 对 H3K79 的甲基化（H3K79me）。这一突破表明 H4Kac/H2Bub/H3K79me 之间存在串扰，可能有助于我们更好地理解 Dot1/Dot1L 在发育过程和疾病中的作用，包括 MLL1/KMT2A（MLL-r）白血病。
